Oritavancin - Semisynthetic Glycopeptidic Antibiotic

Oritavancin is a semisynthetic glycopeptidic antibiotic with a long half-life allowing the administration as single dose (1200 mg) by intravenous infusion over 3 hours. It has three mechanisms of action: (i) inhibition of the transglycosylation (polymerization) step of cell wall biosynthesis by binding to the stem peptide of peptidoglycan precursors; (ii) inhibition of the transpeptidation (crosslinking) step of cell wall biosynthesis by binding to the peptide bridging segments of the cell wall; and (iii) disruption of bacterial membrane integrity, leading to depolarization, permeabilization, and rapid cell death. Oritavancin has been approved in the US and in EU for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.